2. Signalwege
  3. Metabolic Enzyme/Protease
  4. Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Phosphodiesterase (PDE)

Related Products

PDF 4.17 MB

Phosphodiesterase (PDE) is any enzyme that breaks a phosphodiester bond. Usually, people speaking of phosphodiesterase are referring to cyclic nucleotide phosphodiesterases, which have great clinical significance and are described below. However, there are many other families of phosphodiesterases, including phospholipases C and D, autotaxin, sphingomyelin phosphodiesterase, DNases, RNases, and restriction endonucleases, as well as numerous less-well-characterized small-molecule phosphodiesterases. The cyclic nucleotide phosphodiesterases comprise a group of enzymes that degrade the phosphodiester bond in the second messenger molecules cAMP and cGMP. They regulate the localization, duration, and amplitude of cyclic nucleotide signaling within subcellular domains. PDEs are therefore important regulators ofsignal transduction mediated by these second messenger molecules.

Phosphodiesterase (PDE) Isoform Specific Products:

Phosphodiesterase (PDE) Isoform Comparison
Art. -Nr. Produktname Wirkung Reinheit Chemical Structure
  • HY-12788A
    (S)-PF-04449613
    		Inhibitor 99.85%
    (S)-PF-04449613 is the left-handed isomer of PF-04449613 (HY-12788). PF-04449613 is a selective PDE9A inhibitor with an IC50 of 22 nM. PF-04449613 improves motor learning ability in a mouse model.
    (S)-PF-04449613
  • HY-108621
    RS-25344 hydrochloride
    		Inhibitor 99.93%
    RS-25344 hydrochloride is a selective cAMP-phosphodiesterase 4 (PDE 4; PDE IV) inhibitor with an IC50 of 0.28 nM in human lymphocytes. RS-25344 hydrochloride has only weak inhibitory effects on PDE I, II, III (IC50 of >100 μM, 160 μM, 330 μM, respectively). RS-25344 hydrochloride has anti-inflammatory, memory- and cognition enhancing, and antineoplastic effects.
    RS-25344 hydrochloride
  • HY-126233
    PAT-347
    		Inhibitor 98.63%
    PAT-347 is an Autotaxin (ATX) inhibitor. ATX is a secretory enzyme that hydrolyzes lysophosphatidylcholine (LPC) and regulates lysophosphatidic acid (LPA) production in the blood.
    PAT-347
  • HY-50865
    PDE-9 inhibitor
    		Inhibitor 99.79%
    PDE-9 inhibitor is a potent PDE-9 inhibitor. PDE-9 inhibitor can be used for neurodegenerative diseases, such as Alzheimer's disease and schizophrenia.
    PDE-9 inhibitor
  • HY-N8092
    Kushenol B
    		Inhibitor
    Kushenol B is an isoprenoid flavonoid isolated from S. flavescens, has antimicrobial, anti-inflammatory and antioxidant activities. Kushenol B has inhibitory activity against cAMP phosphodiesterase (PDE), with an IC50 of 31 µM.
    Kushenol B
  • HY-108623
    Atizoram
    		Inhibitor
    Atizoram (CP-80,633) is an orally active phosphodiesterase type 4 (PDE4) inhibitor. Atizoram blocks cAMP degradation, thereby increasing intracellular and plasma cAMP levels. Atizoram inhibits TNFα release. Atizoram can be used in research related to acute respiratory distress syndrome.
    Atizoram
  • HY-90009D
    (6S,12aR)-Tadalafil
    		Inhibitor 99.48%
    (6S,12aR)-Tadalafil (Tadalafil EP Impurity C) is a highly potent PDE5 inhibitor with an IC50 value of 5 nM and has blood pressure lowering activity.
    (6S,12aR)-Tadalafil
  • HY-100118
    BW-A 78U
    		Inhibitor 99.67%
    BW-A 78U is a PDE4 inhibitor with an IC50 of 3 μM.
    BW-A 78U
  • HY-182638
    CPL500036
    		Inhibitor
    CPL500036 is an orally active, blood-brain barrier permeable phosphodiesterase 10A (PDE10A) inhibitor with IC50 values of 1 nM (Reference 1) and 35 nM (Reference 2). CPL500036 acts as a negative allosteric modulator of the M2 muscarinic receptor with an IC50 of 9.2 μM. CPL500036 alters cyclic nucleotide levels in basal ganglia circuits, inhibits the hydrolysis of cAMP and cGMP, and suppresses hERG potassium channel tail currents. CPL500036 induces catalepsy in rats and reverses injury-induced contralateral forelimb use impairment. CPL500036 can be used in research related to schizophrenia, Parkinson's disease, and levodopa-induced dyskinesia.
    CPL500036
  • HY-106739
    Motapizone
    		Inhibitor
    Motapizone (NAT 05-239) is a selective PDE3 inhibitor. Motapizone moderately inhibits cytokine release in lipopolysaccharide (LPS)-induced alveolar macrophages. Motapizone also inhibits human platelet aggregation by increasing intracellular cAMP.
    Motapizone
  • HY-115871
    PDE4-IN-4
    		Inhibitor
    PDE4-IN-4 is a dual M3 (pIC50 = 10.2) antagonist-PDE4 (pIC50 = 8.8) inhibitor for the inhaled research of pulmonary diseases.
    PDE4-IN-4
  • HY-P2936A
    Sphingomyelin phosphodiesterase, Bacillus cereus
    Sphingomyelin phosphodiesterase, Bacillus cereus is a sphingomyelin hydrolase and Insecticide. Sphingomyelin phosphodiesterase, Bacillus cereus catalyzes the decomposition of sphingomyelin into ceramide and phosphorylcholine. Sphingomyelin phosphodiesterase, Bacillus cereus causes rapid paralysis and death in injected insects, including German cockroaches and black cutworms. Sphingomyelin phosphodiesterase, Bacillus cereus reduces H2O2 production. Sphingomyelin phosphodiesterase, Bacillus cereus can be used in studies related to sepsis and endophthalmitis.
    Sphingomyelin phosphodiesterase, Bacillus cereus
  • HY-170788
    PDE7A-IN-1
    		Inhibitor 99.83%
    PDE7A-IN-1 is an orally active and selective PDE7A inhibitor with an IC50 of 0.0037 μM against PDE7A. PDE7A-IN-1 shows excellent isozyme selectivity over PDE7B. PDE7A-IN-1 elevates intracellular cAMP levels, suppresses ECR5 enhancer activity and reduces sclerostin expression. PDE7A-IN-1 significantly increases bone mineral density in rats. PDE7A-IN-1 can be used for the study of osteoporosis.
    PDE7A-IN-1
  • HY-N10149
    Nauclefine
    		Modulator 99.65%
    Nauclefine is an indole alkaloid isolated from Nauclea officinalis. Nauclefine acts as a PDE3A modulator to induce cancer cell apoptosis through a PDE3A-SLFN12-dependent death pathway.
    Nauclefine
  • HY-106477
    Quazinone
    		Inhibitor 99.7%
    Quazinone is a selective inhibitor of cGMP-inhibited-phosphodiesterase (cGI-PDE, PDE3). Quazinone inhibits the phosphorylation of p42/p44 MAP kinase. Quazinone possesses antimitogenic effect .
    Quazinone
  • HY-120246
    GS-5759
    		Inhibitor 99.21%
    GS-5759 is both a β₂-adrenergic receptor agonist and a PDE4 inhibitor. GS-5759 increases intracellular cAMP levels by activating the β₂ receptor, promoting bronchial dilation. GS-5759 inhibits PDE4 activity, reduces cAMP degradation, and enhances anti-inflammatory effects. GS-5759 exhibits potent bronchial dilation and anti-inflammatory capabilities in animal models. GS-5759 can be used for research on respiratory diseases such as chronic obstructive pulmonary disease (COPD).
    GS-5759
  • HY-135632
    Hydroxychlorodenafil
    		Inhibitor 99.6%
    Hydroxychlorodenafil (compound 40) is a phosphodiesterase (PDE) inhibitor. Hydroxychlorodenafil can be used in cancer research.
    Hydroxychlorodenafil
  • HY-121381
    Kuraridine
    		Inhibitor 98.0%
    Kuraridine is a prenylated flavonol extract from the roots of Sophora flavescens. Kuraridine has an inhibitory effect on cGMP specific phosphodiesterase type 5 (PDE5) (IC50=0.64 μM).
    Kuraridine
  • HY-108047
    MK-0873
    		Inhibitor
    MK-0873 is a selective phosphodiesterase-4 (PDE4) inhibitor. MK-0873 increases intracellular levels of cyclic adenosine phosphate (cAMP) by inhibiting the activity of the PDE4 enzyme and subsequently activates protein kinase A (PKA). Activated PKA inhibits the activity of inflammatory cells and leads to direct relaxation of airway smooth muscle. MK-0873 can be used in studies of chronic obstructive pulmonary disease (COPD).
    MK-0873
  • HY-108045
    Lodenafil carbonate
    		Inhibitor 98.0%
    Lodenafil carbonate, a dimer that acts as a proagent delivering Lodenafil in vivo, is an orally active phosphodiesterase type 5 (PDE5) inhibitor for the treatment of erectile dysfunction (ED).
    Lodenafil carbonate
Art. -Nr. Produktname / Synonyms Application Reactivity
Phosphodiesterase (PDE) Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.